Evidence map›Paper›PMID 18323436›Full record

ArticleScience (New York, N.Y.)2008

Medicine. Moving toward transparency of clinical trials.

Deborah A Zarin, Tony Tse

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. VO: The Vaccine Ontology.Scientific data · 2026
    Article
  9. Article
  10. VO: The Vaccine Ontology.bioRxiv : the preprint server for biology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Current status of Bayesian clinical trials for oncology, 2020.Contemporary clinical trials communications · 2020
    Review
  18. Article
  19. P-hacking in clinical trials and how incentives shape the distribution of results across phases.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Deborah A ZarinNational Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20894, USA. dzarin@mail.nih.gov
Tony Tse

Funding

ClinicalTrial Registration and Results ReportingZ01LM008926 · NLM · NATIONAL LIBRARY OF MEDICINE · PI ZARIN, DEBORAH · 2008 to 2008
$938k
Intramural NIH HHS Z99 LM999999
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Access to InformationClinical Trials as TopicRegistriesAdverse Drug Reaction Reporting SystemsDatabases, FactualDisclosureHumansIntellectual PropertyProduct Surveillance, PostmarketingPublic PolicyPublishingUnited StatesUnited States Food and Drug Administration

Identifiers

PMID18323436
PMCPMC2396952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.